Summary
In reviewing the current state of affairs in radioimmunotherapy the paper focuses on the main difficulties thus far encountered and the procedures designed to avoid or circumvent these problems. The long range β-emitters90Y and188Re have replaced131I as the isotopes currently receiving most attention for use in radioimmunotherapy, and a range of new chelators are under investigation for in vivo stability and immunogenicity. Approaches aimed at improving tumour targetting and antigen expression such as two-step pretargetting techniques, tumour necrosis treatment and cytokine pretreatment are summarised. Methods designed to improve host-Mab interactions are outlined and the need to incorporate successful ideas from current cancer therapies is emphasised.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams PG, Carrasquillo JA, Schroff RW, Eary JF, Fritzberg AR, Morgan AC, Wilbur DS, Beaumier PL, Larson SM, Nelp WB (1987) Imaging and therapy of metastatic carcinoma with radiolabeled monoclonal antibodies. Princ Cancer Biother 337–354
Bejent RHJ (1989) Dosimetry and suppression of the anti-mouse response in131I labelled antibody therapy of cancer. Br J Cancer 59: 305
Benjamin RJ, Waldmann H (1986) Induction of tolerance by monoclonal antibody therapy. Nature 320: 449
Boyd JE, James K (1989) Human monoclonal antibodies: their potential, problems and prospects. Adv Biotechnol Processes 11: 1–43
Bosslet K, Steinstraesser A, Hermentin P, Kuhlman L, Broynck A, Magerstaedt M, Seemann G, Schwarz A, Sedlacek HH (1991) Generation of bispecific monoclonal antibodies for two-phase radioimmunotherapy. In: Epenetos AA (ed) Monoclonal antibodies, applications in clinical oncology. Chapman & Hall, Lond, pp 167–178
Britton KE (1991) Overview of radioimmunotherapy: a European perspective. Antibody Immunoconjugates Radiopharmaceuticals 4: 133–150
Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MS, DeNardo GL, Meares CF (1990) Yttrium-90 labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 31: 473–479
Epstein AL, Chen FM, Taylor CR (1988) A novel method for the detection of necrotic lesions in human cancers. Cancer Res 48: 5842–5848
Epstein AL, Chen FM, Ansari A, Najafi A, Siegel M, Lee K, Hu E, Rosen P, Watkins P, Stain S, Wearer F, Taylor C (1991) Radioimmunodetection of necrotic lesions in human tumours using I-131 labelled TNT-1 F(ab′)2 monoclonal antibody. Antibody Immunoconjugates Radiopharmaceuticals 4: 151–161
Goldenberg DM, Blumenthal RD, Sharkey RM (1990) Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol 1: 217–225
Hnatowich DJ, Virzi F, Rusckowski M (1987) Investigations of avidin and biotin for imaging applications, J Nucl Med 28: 1294
Hooker GR, Epenetos AA (1986) The intracavitary application of monoclonal antibodies as vehicles for therapeutic radionucleotides. In: Schubiger PA and Hassler PH (eds) Radionuclides for therapy. Roche Scientific Service Publications, pp 183–199
Humm JL (1986) Dosimetric aspects of radiolabeled antibodies for tumour therapy. J Nucl Med 27: 1491–1497
Kohler S, Milstein G (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497
Kosmas C, Snook D, Hird V, Gooden GS, Verhoeyen M, Courtenay-Luck NS, McCall MJ, Meares C, Epenetos AA (1991) Immune responses against the macrocyclic chelating agent (DOTA) in patients receiving anti-tumour monoclonal antibodies for imaging and therapy. Proc 8th Int Hammersmith Meet. Advances in the applications of monoclonal antibodies in clinical oncology. p 61
Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J (1989) In vitro and in vivo targetting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30: 1358–1366
Moi MK, Meares CF, De Nardo SJ (1988) The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetracetic acid, and study of its yttrium (III) complex. J Am Chem Soc 110: 6266
Paganelli G, Malcovati M, Fazio F (1991) Monoclonal antibody pretargetting techniques for tumour localisation: the avidin-biotin system. Nucl Med Commun 12: 211–234
Philpott GW, Shearer WT, Bower JR, Parker CW (1973) Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol 111: 921
Pimm MV, Fells HF, Perkins AC, Baldwin RW (1988) Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody. Nucl Med Commun 5: 931–941
Riechmann L, Clark M, Waldman H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332: 323–327
Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JV (1988) Interferon-induced changes in pharmacokinetics and tumour uptake of111In-labelled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80: 160–165
Rowlinson-Busza G, Bamias A, Krausz T, Epenetos AA (1991) Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenographts following intratumour injection. Cancer Res 51: 3251–3256
Sehon AH (1989) Conversion of xenogeneic monoclonal antibodies to specific tolerogens. Br J Cancer 59: 313
Wessels BW, Rogus RD (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumour associated antibodies. Med Phys 11: 638–645
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maraveyas, A., Epenetos, A.A. An overview of radioimmunotherapy. Cancer Immunol Immunother 34, 71–73 (1991). https://doi.org/10.1007/BF01741338
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741338